secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001437749-25-000801
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRXP subsidiary HOPE signs $27M term sheet with Smith & Sauer; $25M preferred equity, $2M common
--------------------------------------------------------------------------------

- Smith & Sauer to purchase $25M Series A Preferred in HOPE convertible into 1/3 of fully diluted equity, with 15% dividend.
- $2M purchase of NRXP common at $2.75/share (above recent close); investor also buys 500K shares from existing holders at $2.75.
- Warrants for 3M NRXP shares at $3.00/sh with 24-month term, plus royalties on product sales up to $250M cumulative return.
- Smith & Sauer gets board seats at both HOPE and NRXP; funding to support clinic acquisitions and NRX-100/NRX-101 development.
- Closing subject to definitive agreements and standard conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925000801/0001437749-25-000801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925000801/nrxp20250109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-000801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer